Cue biopharma reports third quarter 2024 financial results and recent business highlights

Boston, nov. 14, 2024 (globe newswire) -- cue biopharma, inc.  (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific t cells for the treatment of cancer and autoimmune disease, today provided a business and financial update for the third quarter of 2024.
CUE Ratings Summary
CUE Quant Ranking